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Background: Polymyalgia Rheumatica (PMR) is the commonest inflammatory condition seen in older patients in
primary care. To date, however, research has been focused on secondary care cohorts rather than primary care
where many patients are exclusively managed. This two year prospective inception cohort study of PMR patients
will enable us to understand the full spectrum of this condition.
Methods: Patients diagnosed with PMR in primary care will be identified via Read codes and mailed a series of
postal questionnaires over a two-year period to assess their levels of pain, stiffness and functioning, as well as
medication usage and other health-related and socio-demographic characteristics. In addition, participants will be
asked for permission to link their survey data to their general practice electronic medical record and to national
mortality and cancer registers.
Discussion: This will be the first large-scale, prospective, observational cohort of PMR patients in primary care. The
combination of survey data with medical records and national registers will allow for a full investigation of the
natural history and prognosis of this condition in the primary care setting, in which the majority of patients are
treated, but where little research on the treatment and outcome of consultation has been undertaken. This will
provide information that may lead to improved primary care management of PMR.
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In the UK, Polymyalgia Rheumatica (PMR) is the most
common inflammatory rheumatic disease in adults aged
50 years and over, and is characterised by pain and stiff-
ness in the shoulder and hip girdles and an elevated acute
phase response [1]. On an international scale, the condi-
tion is known to increase with more Northerly latitude
[2], but within the UK, PMR has been found to be more
common in the South than in the North [3].
Whilst less common than other inflammatory arthropa-
thies, such as Rheumatoid Arthritis, PMR is the common-
est inflammatory disorder of older adults. In the UK, the
estimated annual incidence is variable, ranging from
0.01 % to 0.08 % in those aged 40 years and over [3-5].* Correspondence: s.muller@cphc.keele.ac.uk
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reproduction in any medium, provided the orCrowson et al [6] estimate the life-time risk of PMR in the
US to be 2.4 % for females and 1.7 % for males. In the
same population, the annual incidence has been estimated
to be between 0.5 % and 0.6 % [7,8]. With the ageing
population [9], the number of patients with PMR is set to
rise.
Health care systems vary between countries, but in the
UK the majority of patients with PMR are managed exclu-
sively in primary care [5,10]. Despite this, the majority of
PMR research has been in the secondary care setting,
which is likely to represent those with more severe disease
than those managed solely in primary care. GPs are cur-
rently unable to offer their patients evidenced-based infor-
mation regarding the prognosis of their condition,
because there has not been a study of the course of PMR
in primary care. Indeed, there is so little research examin-
ing the long-term prognosis of PMR, that there are noLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cently has a definition of remission been suggested [11].
The recommended treatment for PMR is low dose cor-
ticosteroids, where the dose is tapered over a period of
up to two years. This makes PMR one of the most com-
mon reasons for the long-term use of steroid therapy
[1], and consequently has the potential to put PMR
patients at increased risk of steroid-related complica-
tions, such as fractures and gastro-intestinal bleeding.
Furthermore, there are some data to suggest that
patients with PMR have increased mortality rates [12],
although other studies have shown no such association
[13].
Given the non-specific nature of some of the present-
ing symptoms such as joint pain and morning stiffness,
recent diagnostic guidelines [1] have emphasised the
need to exclude alternative diagnoses such as Rheuma-
toid Arthritis or malignancy, which may initially present
in a similar manner and may also improve (at least in
the early stages) with corticosteroid treatment. Little is
known about the patterns of consultation of such
patients or clinical predictors of PMR.
The long-term outcomes of patients with PMR are,
largely unknown, particularly in the primary care popu-
lation. This paper outlines the proposed protocol for an
inception cohort of primary care patients receiving a
diagnosis of PMR in the UK.
Objectives
The overall aim of this study is to assess the epidemi-
ology of PMR in general practice.
Specific objectives in order to meet this aim include:
1. Describe the natural history and prognosis of PMR
in primary care;
2. Identify the frequency of alternative diagnoses in
those originally diagnosed with PMR;
3. Identify appropriate outcome measures for PMR in
primary care;
4. Assess the association between PMR disease activity
and quality of life;
5. Identify the patterns of PMR-related disability over a
two-year period;
6. Describe the use of corticosteroids by patients with
PMR over a two year period, and how this relates to
pain and stiffness outcomes;
7. Assess clinical practice versus audit standards
specified in British Society for Rheumatology [1] and
the Royal College of Physicians [14] guidelines.
Methods/design
This study has received ethical approval from the
Staffordshire Local Research Ethics Committee (REC
reference number: 12/WM/0021).Design
Prospective observational inception cohort recruited in
UK primary care.
Sampling frame
All adults (aged ≥18 years) registered with approximately
200 general practices, presenting at the practice and re-
ceiving a new Read-coded diagnosis of PMR between
June 2012 and June 2014.
Patient eligibility
Inclusion criteria
 Aged 18 years and over.
 Registered with a participating general practice
during the study period.
 First Read-coded consultation for PMR in the last
three years occurred during the study period.
 Provided written informed consent to primary care
medical record review.
Exclusion criteria
 Less than 18 years of age.
 Vulnerable groups, e.g. significant cognitive
impairment, dementia, severe/terminal illness.
 Previous PMR diagnostic code in the last three
years.
Recruitment procedure
Patient identification
Eligible patients will be identified via one of two meth-
ods: Method A and Method B. The different methods
will be applied in different practices, according to prac-
tice preference and local recruitment systems. In both
methods, when a patient consults with a new diagnosis
of PMR and the general practitioner (GP) enters an ap-
propriate PMR Read code (N20..), a pop-up window will
appear, reminding the GP of the study. This window will
request that, if they have not already done so, the GP
orders the blood tests recommended for the diagnosis of
PMR [1] and that they give the patient a postcard con-
taining details of the study.
In Method A, in addition to the blood test and post-
card reminder, the pop-up window will ask the GP to
discuss the study with the patient and gain their consent
to be contacted by the Research Centre. The GP will
then be asked to complete a fax form and return to the
Research Centre with the patient’s name, gender, date of
birth, address, NHS number, practice identifier and con-
firmation that he/she has a new diagnosis of PMR. On
receipt of the fax by the Research Centre, the patient’s
details will be entered into a secure mailing database.
The fax form will be stored in a secure filing cabinet.
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Care Research Network (PCRN) will conduct fortnightly
electronic searches of the primary care records in par-
ticipating practices in order to identify patients with a
new diagnosis of PMR.
The patient identification process will not interfere
with routine primary care management except in that all
participating general practices will be provided with cop-
ies of the British Society for Rheumatology guidelines
for the management of PMR [1] and encouraged to re-
quest the recommended blood tests.
Initiating patient contact
Eligible patients identified by Method A will be sent a
Study Pack from the Research Centre, containing a cover
letter and Participant Information Sheet inviting them to
take part and giving further details about the study. The
name, contact telephone number and email address of the
Principal Investigator will be provided should potential
participants have any questions regarding the study. The
Study Pack will also contain a Baseline Questionnaire with
Consent Form and a stamped addressed envelope. For
patients identified through Method B, the study pack willCons
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Table 1 Self-complete postal questionnaire. Conceptual domains, operational definitions and empirical measures
Conceptual domain Operational definition Empirical measure Number of
items
Time
point
PMR symptoms
PMR-related pain Level of pain attributed to PMR
at time of questionnaire
Numerical rating scale (0–10) of pain
intensity
1 ALL
PMR-related stiffness Level of stiffness attributed to PMR
at time of questionnaire
Numerical rating scale (0–10) of
stiffness
1 ALL
Pain and stiffness
locations
Pain shaded in hips and shoulders
to define PMR.
Manikin (Figure 2) 2 ALL
Daily stiffness pattern Periods of day with stiffness
in the past week
None/Morning/Lunchtime/
Afternoon/Early evening/ Late
evening/During the night
1 ALL
Morning stiffness Duration of stiffness from time of
waking in the past week
None/1 to 15 minutes/16 to 45 minutes/
46 minutes to an hour/More than an hour
1 ALL
Delay in patient
consultation
Symptom chronicity at presentation to GP Less than a week/1 to 2 weeks/
2 to 4 weeks/More than 4 weeks
1 BL
Delay in GP diagnosis Number of consultations with GP
before receiving diagnosis
1/2/3/4 or more 1 BL
Shoulder movement Ability to raise both arms above head
at time of questionnaire
Yes/No 1 ALL
Patient perceived
recovery
Patient’s self-perceived rating of recovery 6 category scale (Completely recovered
through to Much worse)
1 1FU, 4FU,
8FU, 12FU,
18FU, 24FU
PMR Medications
Corticosteroid dose Current daily dose of prednisolone Free text 1 ALL
Other medication use Reported use of (i) Paracetamol,
(ii) paracetamol + codeine, (iii) non-steroidal
anti-inflammatories, (iv) strong analgesics,
(v) gastro-intestinal protection,
(vi) calcium+ vitamin D, (vii) osteoporosis
treatment, (viii) alternative therapies,
(ix) anti-depressants, (x) other
Yes/No(free text for Other) 10 BL
General health and other medical problems
General health Self-rated health at time of questionnaire
Global health rating
EuroQoL [16]Excellent/Very good/
Good/Fair/Poor
51 BL, 12FU,
24FU
ALL
Falls Falls in previous 12 months Yes/No 1 BL, 12FU,
24FU
Osteoporosis Ever fractured (i) hip, (ii) wrist,
(iii) spine/vertebrae, (iv) other
Yes/No 4 BL, 12FU,
24FU
PMR exclusion
symptoms
Reports of recent (i) Sudden headache,
(ii) Tender scalp, (iii) Disturbed/double vision,
(iv) Jaw claudication, (v) Temperature,
(vi) Appetite loss, (vii) Unintentional
weight loss, (viii) Joint swelling, (ix) Other
Yes/No(free text for Other) 9 BL
Dyspepsia Bothersomeness of dyspepsia symptoms
(ulcer, wind, indigestion, heartburn)
at time of questionnaire
Seeking of healthcare of dyspepsia
symptoms (if present)
Not at all bothered/Bothered a little/
Bothered a lotDid not seek help/
Went to GP/Went to hospital/
Other type of care
11 4FU, 12FU,
24FU
4FU, 12FU,
24FU
Daily activities
Activities of daily
living
Performance in daily activities in past week Modified Health Assessment
Questionnaire [17] adapted to UK
English [18]
8 ALL
Fatigue and sleep
Fatigue Fatigue symptoms in past week Functional Assessment of Chronic
Illness Therapy-Fatigue (Version 4) [19]
13 BL, 1FU,
12FU, 24FU
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Table 1 Self-complete postal questionnaire. Conceptual domains, operational definitions and empirical measures
(Continued)
Sleep Insomnia symptoms in past 2 weeks
(including Diagnostic and Statistical
Manual of Mental Disorders insomnia definition)
Insomnia Severity Index [20] 7 BL, 1FU,
12FU, 24FU
Anxiety and depression
Generalised anxiety
disorder
Anxiety symptoms in past two weeks Generalized Anxiety Disorder-7 [21] 7 BL, 1FU,
12FU, 24FU
Depression Depression symptoms in past two weeks PHQ-8 [22] 8 BL, 1FU,
12FU, 24FU
Socio-demographics
Age Age at diagnosis Date of birth 1 ALL
Sex Sex Male/Female 1 ALL
Ethnicity Ethnicity White/Mixed, multiple ethnic groups/
Asian, Asian British/Black, African,
Caribbean, Black British/Other
1 BL
Employment status Employment status at time of questionnaire Employed/ Unemployed, seeking work/
House-wife/Retired/Not working due to
ill health/Other
1 BL, 1FU,
4FU, 12FU,
18FU, 24FU
Work situation Level of work at time of questionnaire
(in those in reporting being employed
as their employment status)
Doing usual job/ Working fewer hours/
Paid sick leave/Paid annual leave, holiday/
Doing lighter duties/Unpaid leave
1 BL, 10FU,
4FU, 12FU,
18FU, 24FU
Socioeconomic status Occupational class based on
(i) current or (ii) most recent job title
Job title – categorised as manual/
non-manual according to SOC 2010 [23]
1 BL
Lifestyle
Smoking Smoking status at time of questionnaire Never/Previous/Current 1 BL
Alcohol Frequency of drinking at time of
questionnaire
Daily or almost daily/
3 or 4 times a week/
Once or twice a week/
1 to 3 times a month/
Special occasionsonly/Never
1 BL
Obesity BMI at time of questionnaire Height (m/ft)Weight (kg/st, lb) 11 BLBL, 12FU,
24FU
Relationships and social support
Living arrangement Live alone Yes/No 1 BL, 24FU
Marital status Marital status at time of questionnaire Married/Separated/Divorced/Widowed/
Cohabiting/Single
1 BL, 12FU,
24FU
PMR interference with
sexual relationships
Interference with intimate and sexual
relationships
Not applicable/Not at all/ Little bit/
Moderately/Quite a bit/Extremely
(adapted from [24])
1 BL, 12FU,
24FU
Social support Availability of instrumental support
Availability of emotional support
Yes/No/No need [25]Yes/No/No need 11 BL, 12FU,
24FU
Views on PMR and information on the condition
Origin PMR Cause of PMR Free text 1 BL
Information regarding
PMR
Information given by GPGP information
from GP useful
Desire for more information from GP
Searched elsewhere for information
Yes/NoYes/NoYes/NoYes/No 1111 BL
Worries regarding
PMR
Flares Yes/No 1 24FU
Medications Yes/No 1
Reducing medications Yes/No 1
Side-effects of medication Yes/No 1
Yes/No 1
Long-term consequences of PMR Yes/No 1
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Table 1 Self-complete postal questionnaire. Conceptual domains, operational definitions and empirical measures
(Continued)
Other
Potentially useful for
PMR patients in the
future
Information Yes/No and Received Yes/No 2 24FU
Medications Yes/No and Received Yes/No 2
Alternative medications Yes/No and Received Yes/No 2
Yes/No and Received Yes/No 2
Complementary therapies Yes/No and Received Yes/NoYes/No
and Received Yes/No
2
Physiotherapy Yes/No and Received Yes/No 2
Referral to secondary care 2
Other
ALL =All follow-ups; BL = Baseline; 1FU = 1-month follow-up; 4FU = 4-month follow-up; 8FU = 8-month follow-up; 12FU= 12-month follow-up; 18FU= 18-month
follow-up; 24FU= 24-month follow-up.
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below, but will not have their medical record accessed.
Consenting responders
Participants who return their Baseline Questionnaire
and provide written informed consent to medical record
review will be sent a Follow-up Questionnaires at one,
four, eight, 12, 18 and 24 months after Baseline. Their
medical records will be accessed as described below.
A flowchart of the process of recruitment and follow-
up is provided in Figure 1.
Data collection
Medical record review
Where electronic data quality and practicalities allow,
full electronic medical records of consenting participants
will be accessed and securely downloaded to obtain in-
formation on symptoms, diagnoses, prescriptions andMutually exclusive pain areas
Figure 2 Pain and stiffness manikins: definition of hips and shoulders
areas 44, 45, 46 and 47 [26].referrals. This data will be downloaded for the two years
prior to diagnosis and for the two years of follow-up
after diagnosis. Where electronic coding is not routine
practice, or where downloading of data is impractical, a
research nurse from the PCRN will visit practices and
record salient data using a standardised proforma.
For validation purposes, records will be reviewed by a
rheumatologist for the six months following PMR diagno-
sis. This review will use recorded symptoms, blood test
results and examine for alternative diagnoses (e.g. malig-
nancy). This review will be based on recent guidance from
European League Against Rheumatism-American College
of Rheumatology concerning classification criteria for
PMR [15].
Self-complete postal questionnaires
The self-complete postal questionnaires will provide infor-
mation on the descriptive characteristics of participants,Neck and Hip Pain
. Shoulders are defined as areas 3, 7, 24 and 28. Hips are defined as
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detailed prognostic information. The conceptual domains,
operational definitions, and empirical measures used are
provided in Table 1.
Data entry, coding, cleaning and storage
Data will be pseudonymised and entered into a database
specifically designed for this study. Prior to data entry, this
database will be tested using a set of dummy data. Data
will be entered as the completed questionnaires are
received by dedicated members of the administration
team. They are experienced in data entry. The Principal
Investigator will determine coding prior to data entry. The
database will provide coding options, to facilitate the entry
of data. Some standard codes (e.g. missing data (−9), not
applicable (−88)) are used by the Research Centre and will
be utilised in this study.
A different member of the team will then check every
tenth questionnaire as part of the quality assessment
process. This information is kept by the Research Support
Co-ordinator. Data will be stored in a password protected
database and overseen by the Study Data Custodian. Only
members of the research team will have access to the data.
Requests for access to the data must be made in writing,
along with an analysis plan, to the Principal Investigator.
Completed questionnaires will be securely stored separ-
ately from the fax and consent forms, to protect the confi-
dentiality of participants.
Sample size
PMR is a relatively rare condition in primary care and so
the size of this study is constrained by practicalities to
ensure a representative sample of patients for whom
good quality data can be collected. From the CiPCA
database [27], it can be estimated that for every 10,000
primary care patients aged 40 years and over, approxi-
mately 11 will receive a diagnosis of PMR in a 12-month
period (Kelvin Jordan – personal communication). Using
a stricter definition to define PMR, similar to that to be
applied in this study, Smeeth et al [3] estimated that 8
per 10,000 patients in this age group experience a new
onset of PMR every year. With an average practice list
size of 5,000 (approximately half of whom will be aged
40 years or over), a two-year recruitment period, in 200
practices should enable identification of 1,100 patients
with a Read-coded diagnosis of PMR, of whom 800
would be expected to have definite PMR according to
the Smeeth definition [3]. Based on previous experience
of this type of study in our Research Centre [28,29], we
expect that 75 % of patients will respond to the ques-
tionnaire with 80 % of these consenting to have their
medical records reviewed. This will result in an initial
sample of 600 patients, with 480 forming the cohort that
has agreed to medical record review. Allowing for lossto follow-up of 5 % per annum, this should leave a sam-
ple of approximately 430 patients at the end of the two
year follow-up period.Statistical analysis
A descriptive summary of those consenting and not con-
senting to join the cohort will be provided, as will a de-
scription of loss-to-follow-up in the cohort over the two
years of the study.
The psychometric properties of the Modified Health
Assessment Questionnaire (MHAQ) [17] will be investi-
gated to assess its suitability for use in this population.
The recently proposed clinical criteria for remission and
relapse in PMR [11] will also be implemented to investi-
gate their feasibility in primary care epidemiological
studies.
With these findings in mind, regression models will be
used to describe the natural history and prognosis of
PMR over a two-year period. These models will take into
account PMR-related disability, as well as quality of life,
sexual functioning and work disability, and will incorp-
orate both self-reported constructs and information
derived from medical records. The average daily dose of
corticosteroids will be calculated and modelled as a po-
tential prognostic factor for disease activity and new
onset comorbidities.
An overall prognostic model for the chosen outcome
in PMR over two years will be derived and tested.
Where necessary, multiple imputation techniques will
be used to assess the impact of loss-to-follow-up.Discussion
To our knowledge, there has been no previous primary
care inception cohort study of PMR. This study will fill
this gap, by collecting detailed information via postal
questionnaires and medical record review (where con-
sent is given), from patients receiving a new primary
care diagnosis of PMR. This study will provide guidance
on the optimal methods of outcome assessment for
PMR in primary care, and will develop new prognostic
models, relevant to clinical practice in this group. This
study should ultimately lead to improved outcomes for
older patients diagnosed with this common inflamma-
tory condition.
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